BRPI0918555A2 - anticorpo, composição, molécula de ácido nucleico, método de tratamento de um tumor maligno em um animal, e, uso da composição. - Google Patents
anticorpo, composição, molécula de ácido nucleico, método de tratamento de um tumor maligno em um animal, e, uso da composição.Info
- Publication number
- BRPI0918555A2 BRPI0918555A2 BRPI0918555A BRPI0918555A BRPI0918555A2 BR PI0918555 A2 BRPI0918555 A2 BR PI0918555A2 BR PI0918555 A BRPI0918555 A BR PI0918555A BR PI0918555 A BRPI0918555 A BR PI0918555A BR PI0918555 A2 BRPI0918555 A2 BR PI0918555A2
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- antibody
- animal
- treating
- nucleic acid
- Prior art date
Links
- 201000011510 cancer Diseases 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9868508P | 2008-09-19 | 2008-09-19 | |
PCT/GB2009/051216 WO2010032059A2 (en) | 2008-09-19 | 2009-09-18 | Targeted binding agents directed to cd105 and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0918555A2 true BRPI0918555A2 (pt) | 2016-05-03 |
Family
ID=41263674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0918555A BRPI0918555A2 (pt) | 2008-09-19 | 2009-09-18 | anticorpo, composição, molécula de ácido nucleico, método de tratamento de um tumor maligno em um animal, e, uso da composição. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20100196398A1 (pt) |
EP (1) | EP2344541A2 (pt) |
JP (1) | JP2012502649A (pt) |
KR (1) | KR20110057245A (pt) |
CN (1) | CN102388067A (pt) |
AU (1) | AU2009294414A1 (pt) |
BR (1) | BRPI0918555A2 (pt) |
CA (1) | CA2737667A1 (pt) |
WO (1) | WO2010032059A2 (pt) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120098932A (ko) | 2003-06-27 | 2012-09-05 | 암젠 프레몬트 인코포레이티드 | 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도 |
CN101506235B (zh) | 2006-09-01 | 2012-07-25 | 人类多细胞株治疗学公司 | 人或人源化免疫球蛋白在非人转基因动物中增强的表达 |
IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
JP5810413B2 (ja) | 2008-12-19 | 2015-11-11 | バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー | ヒト抗アルファシヌクレイン自己抗体 |
US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
EP2542696B1 (en) | 2010-03-01 | 2016-09-28 | Caris Life Sciences Switzerland Holdings GmbH | Biomarkers for theranostics |
AU2011237669B2 (en) | 2010-04-06 | 2016-09-08 | Caris Life Sciences Switzerland Holdings Gmbh | Circulating biomarkers for disease |
EP2632951B1 (en) * | 2010-10-27 | 2017-08-02 | Amgen Inc. | Dkk1 antibodies and methods of use |
US9315582B2 (en) | 2011-02-23 | 2016-04-19 | Health Research, Inc. | Anti-endoglin antibodies and knockin mice expressing novel human/mouse chimeric endoglin |
EP2681242B1 (en) * | 2011-03-01 | 2018-01-24 | Amgen Inc. | Sclerostin and dkk-1 bispecific binding agents |
US9255595B2 (en) * | 2011-04-29 | 2016-02-09 | Bae Systems Information And Electronic Systems Integration Inc. | Optical dome bezel |
MX357193B (es) | 2011-06-23 | 2018-06-29 | Univ Zuerich | Moleculas de union anti-alfa sinucleina. |
US20130156766A1 (en) * | 2011-11-15 | 2013-06-20 | Allergan, Inc. | Treatment of dry age related macular degeneration |
UA115789C2 (uk) * | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
US10155820B2 (en) | 2014-11-12 | 2018-12-18 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
CN105821029A (zh) * | 2015-01-04 | 2016-08-03 | 彭霞 | 异源融合基因修饰的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法 |
CN113862300A (zh) * | 2015-10-29 | 2021-12-31 | 豪夫迈·罗氏有限公司 | 具有共同轻链的转基因兔 |
CN106928359B (zh) * | 2015-12-30 | 2020-10-13 | 广西医科大学 | 一种CD105纳米抗体Nb59 |
CN106928355B (zh) * | 2015-12-30 | 2020-09-29 | 广西医科大学 | 一种CD105纳米抗体Nb184 |
WO2017218708A1 (en) | 2016-06-14 | 2017-12-21 | Cedars-Sinai Medical Center | Sensitization of tumors to therapies through endoglin antagonism |
MA49947B1 (fr) | 2017-08-22 | 2023-03-31 | Biogen Ma Inc | Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes |
CN108912212B (zh) * | 2018-06-28 | 2019-08-30 | 中山大学附属口腔医院 | 一种与cd105特异性结合的多肽及其应用 |
WO2020106461A2 (en) * | 2018-11-08 | 2020-05-28 | Celldex Therapeutics, Inc. | Anti-mertk antibodies and methods of use thereof |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
WO2021207433A2 (en) * | 2020-04-07 | 2021-10-14 | The Regents Of The University Of California | Epitopes of sars-cov-2 neutralizing antibodies |
CN112426526B (zh) * | 2021-01-25 | 2021-04-06 | 北京达熙生物科技有限公司 | 一种nk细胞的制备方法及其在治疗癌症中的应用 |
CN112876538B (zh) * | 2021-02-04 | 2022-09-30 | 福建医科大学 | 靶向新生血管标记物cd105的多肽及其应用 |
WO2022187710A1 (en) * | 2021-03-05 | 2022-09-09 | Atreca, Inc. | Epha2 antibodies |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023141327A2 (en) * | 2022-01-24 | 2023-07-27 | Genovac Antibody Discovery Llc | Anti-alk1 antibodies and methods of using the same |
WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6190660B1 (en) * | 1996-05-31 | 2001-02-20 | Health Research, Inc. | Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy |
US6323334B1 (en) * | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
ES2609016T3 (es) * | 2000-06-16 | 2017-04-18 | Human Genome Sciences, Inc. | Anticuerpos que se unen inmunoespecíficamente a BLyS |
-
2009
- 2009-09-18 EP EP09785666A patent/EP2344541A2/en not_active Withdrawn
- 2009-09-18 AU AU2009294414A patent/AU2009294414A1/en not_active Abandoned
- 2009-09-18 WO PCT/GB2009/051216 patent/WO2010032059A2/en active Application Filing
- 2009-09-18 CA CA2737667A patent/CA2737667A1/en not_active Abandoned
- 2009-09-18 BR BRPI0918555A patent/BRPI0918555A2/pt not_active IP Right Cessation
- 2009-09-18 US US12/562,533 patent/US20100196398A1/en not_active Abandoned
- 2009-09-18 JP JP2011527406A patent/JP2012502649A/ja not_active Withdrawn
- 2009-09-18 KR KR1020117008833A patent/KR20110057245A/ko not_active Application Discontinuation
- 2009-09-18 CN CN2009801467390A patent/CN102388067A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2010032059A2 (en) | 2010-03-25 |
JP2012502649A (ja) | 2012-02-02 |
WO2010032059A3 (en) | 2010-06-24 |
US20100196398A1 (en) | 2010-08-05 |
CA2737667A1 (en) | 2010-03-25 |
AU2009294414A1 (en) | 2010-03-25 |
CN102388067A (zh) | 2012-03-21 |
EP2344541A2 (en) | 2011-07-20 |
KR20110057245A (ko) | 2011-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0918555A2 (pt) | anticorpo, composição, molécula de ácido nucleico, método de tratamento de um tumor maligno em um animal, e, uso da composição. | |
BRPI0918739A2 (pt) | anticorpo, composição, molécula de ácido nucleico, método de tratamento de tumor maligno em animais, e, uso da composição. | |
LTC2100614I2 (lt) | Antikūnas prieš PDGFR-alfa, skirtas naudoti auglių gydymui | |
BRPI0921687A2 (pt) | Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero. | |
BRPI0922475A2 (pt) | composto, composição farmacêutica , método para tratar câncer, e, uso de um composto. | |
BRPI0813969A2 (pt) | Método para tingir permanentemente o cabelo, e, kit para tingir em substrato queratinoso. | |
BRPI0819819A2 (pt) | Preparações, método e kits ùteis para o tratamento de tosse | |
BR112012003809A2 (pt) | anticorpa monoclonal isolado ou porção de ligação a antígeno do mesmo, composição e, método para tratar câncer em um indivíduo. | |
EA201000146A1 (ru) | Связующее майларда на основе гидроксимонокарбоновой кислоты | |
BRPI0813311A2 (pt) | Composto, métodos para modulara a atividade de uma proteína quinase e para tratar câncer em um indivíduo, e, composição farmacêutica. | |
BRPI0916121A2 (pt) | "métodos para identificar câncer de próstata, método para identificar a presença de uma fusão gênica, kit e uso de uma composição" | |
BRPI0714876A2 (pt) | glucanases, ácidos nucleicos codificando as mesmas e métodos para fabricar e usar as mesmas. | |
BR112012018947A8 (pt) | composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer | |
BRPI0918122A2 (pt) | molécula de diaboy, diaboy, e mólecula dart | |
BRPI0813237A2 (pt) | Composto, método para preparar o composto, composição, medicamento, e, uso do composto. | |
BRPI0919488A2 (pt) | composto, uso de um composto, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto | |
BR112013007229A2 (pt) | ''composição,mistura e processo''. | |
BRPI0915101A2 (pt) | composto, uso do mesmo, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto | |
BRPI0811755A2 (pt) | Amplificação específica de senquência de dna específicas de tumor. | |
BRPI0822218A2 (pt) | Transferases e oxidorredutases, ácidos nucleicos que as codificam e métodos para fazê-las e usá-las. | |
BRPI0911252A2 (pt) | método, extrato, e, composição. | |
BRPI0815057A2 (pt) | Composto, composição farmacêutica, e, método para tratar infecção. | |
BRPI0913300A2 (pt) | composto, processo para o preparo e uso do mesmo, método de tratamento de infecção bacteriana em um animal, e, composição farmacêutica. | |
EP2281903A4 (en) | CANCER MARKER, METHOD FOR EVALUATING CANCER USING THE CANCER MARKER AND ASSESSING THE VALUE | |
BRPI0722053A2 (pt) | método para o tratamento de câncer, formulação anticâncer, método de uso da formulação, e, uso de metoxiamina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |